Milestone Pharmaceuticals (MIST) News Today $0.89 +0.07 (+8.80%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.89 0.00 (-0.21%) As of 04/17/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Milestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVTApril 9, 2025 | seekingalpha.comMilestone Pharmaceuticals price target lowered to $10 from $25 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comTD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertaintyApril 2, 2025 | finance.yahoo.comMilestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD CowenApril 2, 2025 | markets.businessinsider.comMilestone Pharmaceuticals Shares Hit New Low After FDA Rejects EtripamilMarch 29, 2025 | marketwatch.comMilestone Pharmaceuticals (NASDAQ:MIST) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Friday.March 29, 2025 | marketbeat.comMilestone Pharmaceuticals Inc.: FDA Issues Complete Response Letter for Etripamil for PSVTMarch 28, 2025 | finanznachrichten.deMilestone stock tumbles after FDA letter on etripamilMarch 28, 2025 | ca.investing.comMilestone Pharmaceuticals announces FDA issued CRL for etripamilMarch 28, 2025 | markets.businessinsider.comMilestone CRL affirms integrity of clinical data, says H.C. WainwrightMarch 28, 2025 | msn.comUS FDA declines to approve Milestone's heart rhythm nasal spray; shares halveMarch 28, 2025 | msn.comMilestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s PositiveMarch 28, 2025 | msn.comUS FDA declines to approve Milestone Pharma's heart rhythm nasal sprayMarch 28, 2025 | reuters.comFDA Issues Complete Response Letter for Etripamil for PSVTMarch 28, 2025 | globenewswire.comMilestone Pharmaceuticals to present clinical data on etripamilMarch 21, 2025 | markets.businessinsider.comMilestone Pharmaceuticals: A Compelling Value Proposition For Patients And PayersMarch 21, 2025 | seekingalpha.comHC Wainwright Issues Negative Forecast for MIST EarningsMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Stock analysts at HC Wainwright cut their Q1 2025 earnings estimates for Milestone Pharmaceuticals in a research note issued to investors on Monday, March 17th. HC Wainwright analyst P. Trucchio now forecasts that the company will postMarch 21, 2025 | marketbeat.comMilestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of CardiologyMarch 20, 2025 | globenewswire.comHC Wainwright Issues Pessimistic Outlook for MIST EarningsMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Equities researchers at HC Wainwright decreased their FY2028 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a research note issued to investors on Monday, March 17th. HC Wainwright analyst P. Trucchio now anticipateMarch 20, 2025 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a research report on Monday.March 18, 2025 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Sees Significant Growth in Short InterestMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 742,800 shares, a growth of 86.3% from the February 13th total of 398,700 shares. Based on an average trading volume of 817,700 shares, the days-to-cover ratio is presently 0.9 days. Currently, 1.5% of the company's shares are short sold.March 15, 2025 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPSMilestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.04).March 14, 2025 | marketbeat.comMilestone Pharmaceuticals reports Q4 EPS (67c) vs ($1.39) last yearMarch 13, 2025 | markets.businessinsider.comMilestone Pharmaceuticals: Q4 Earnings SnapshotMarch 13, 2025 | sfgate.comMilestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate UpdateMarch 13, 2025 | globenewswire.comMilestone Pharmaceuticals (MIST) Projected to Post Quarterly Earnings on ThursdayMilestone Pharmaceuticals (NASDAQ:MIST) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comMilestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest UpdateMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 398,700 shares, a drop of 17.2% from the January 31st total of 481,400 shares. Based on an average daily trading volume, of 669,500 shares, the short-interest ratio is presently 0.6 days.March 6, 2025 | marketbeat.comMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2025 | globenewswire.comTD Cowen Keeps Their Buy Rating on Milestone Pharmaceuticals (MIST)March 1, 2025 | markets.businessinsider.comMilestone Pharmaceuticals' (MIST) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a research report on Friday.March 1, 2025 | marketbeat.comMilestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.comPiper Sandler Sticks to Their Buy Rating for Milestone Pharmaceuticals (MIST)February 26, 2025 | markets.businessinsider.comMilestone receives notice of allawance from USPTO on etripamil nasal sprayFebruary 19, 2025 | markets.businessinsider.comMilestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for EtripamilFebruary 19, 2025 | globenewswire.comShort Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Declines By 27.9%Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 481,400 shares, a drop of 27.9% from the January 15th total of 667,900 shares. Based on an average trading volume of 612,900 shares, the short-interest ratio is presently 0.8 days.February 15, 2025 | marketbeat.comMilestone Pharmaceuticals to host Commercial Launch Plan investor eventFebruary 11, 2025 | markets.businessinsider.comMilestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025February 11, 2025 | globenewswire.comLoss-Making Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected To Breakeven In The Medium-TermFebruary 3, 2025 | finance.yahoo.comWhat is HC Wainwright's Estimate for MIST Q1 Earnings?Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Stock analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Milestone Pharmaceuticals in a report issued on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will post eaJanuary 29, 2025 | marketbeat.comMilestone Pharmaceuticals provides 2025 corporate outlookJanuary 29, 2025 | markets.businessinsider.comMilestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYCJanuary 28, 2025 | globenewswire.comFY2029 Earnings Estimate for MIST Issued By HC WainwrightMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a research report issued to clients and investors on Monday, January 27th. HC Wainwright analyst P. TrucJanuary 28, 2025 | marketbeat.comH.C. Wainwright maintains $25 target on Milestone sharesJanuary 27, 2025 | msn.comMilestone Pharmaceuticals' (MIST) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a research report on Monday.January 27, 2025 | marketbeat.comMilestone Pharmaceuticals reports inducement grants under Nasdaq listing ruleJanuary 7, 2025 | markets.businessinsider.comMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 7, 2025 | globenewswire.comMilestone Pharmaceuticals (NASDAQ:MIST) Trading Down 8.1% - Time to Sell?Milestone Pharmaceuticals (NASDAQ:MIST) Trading Down 8.1% - Should You Sell?January 3, 2025 | marketbeat.comMilestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 25, 2024 | markets.businessinsider.comMilestone Pharmaceuticals’ CARDAMYST: A Promising Buy with FDA Decision and Phase 3 Trial on HorizonNovember 15, 2024 | markets.businessinsider.comMilestone Pharmaceuticals (MIST) Gets a Buy from Piper SandlerNovember 14, 2024 | markets.businessinsider.com Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address MIST Media Mentions By Week MIST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIST News Sentiment▼-1.000.49▲Average Medical News Sentiment MIST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIST Articles This Week▼11▲MIST Articles Average Week Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VYGR News PRME News INMB News GNFT News IVA News INBX News ANNX News CYBN News AARD News CGC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIST) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MIST Stock Free MIST Stock Alerts